JP2019528082A5 - - Google Patents

Download PDF

Info

Publication number
JP2019528082A5
JP2019528082A5 JP2019517135A JP2019517135A JP2019528082A5 JP 2019528082 A5 JP2019528082 A5 JP 2019528082A5 JP 2019517135 A JP2019517135 A JP 2019517135A JP 2019517135 A JP2019517135 A JP 2019517135A JP 2019528082 A5 JP2019528082 A5 JP 2019528082A5
Authority
JP
Japan
Prior art keywords
domain
antibody
fusion protein
antigen
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019517135A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019528082A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2017/087620 external-priority patent/WO2017211321A1/zh
Publication of JP2019528082A publication Critical patent/JP2019528082A/ja
Publication of JP2019528082A5 publication Critical patent/JP2019528082A5/ja
Priority to JP2021088589A priority Critical patent/JP2021143186A/ja
Priority to JP2024087108A priority patent/JP2024112978A/ja
Pending legal-status Critical Current

Links

JP2019517135A 2016-06-08 2017-06-08 アゴニスト抗体の活性を増強する抗体重鎖定常領域配列 Pending JP2019528082A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021088589A JP2021143186A (ja) 2016-06-08 2021-05-26 アゴニスト抗体の活性を増強する抗体重鎖定常領域配列
JP2024087108A JP2024112978A (ja) 2016-06-08 2024-05-29 アゴニスト抗体の活性を増強する抗体重鎖定常領域配列

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610404956 2016-06-08
CN201610404956.7 2016-06-08
PCT/CN2017/087620 WO2017211321A1 (zh) 2016-06-08 2017-06-08 增强激动型抗体活性的抗体重链恒定区序列

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021088589A Division JP2021143186A (ja) 2016-06-08 2021-05-26 アゴニスト抗体の活性を増強する抗体重鎖定常領域配列

Publications (2)

Publication Number Publication Date
JP2019528082A JP2019528082A (ja) 2019-10-10
JP2019528082A5 true JP2019528082A5 (enExample) 2019-11-21

Family

ID=60578403

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019517135A Pending JP2019528082A (ja) 2016-06-08 2017-06-08 アゴニスト抗体の活性を増強する抗体重鎖定常領域配列
JP2021088589A Pending JP2021143186A (ja) 2016-06-08 2021-05-26 アゴニスト抗体の活性を増強する抗体重鎖定常領域配列
JP2024087108A Pending JP2024112978A (ja) 2016-06-08 2024-05-29 アゴニスト抗体の活性を増強する抗体重鎖定常領域配列

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021088589A Pending JP2021143186A (ja) 2016-06-08 2021-05-26 アゴニスト抗体の活性を増強する抗体重鎖定常領域配列
JP2024087108A Pending JP2024112978A (ja) 2016-06-08 2024-05-29 アゴニスト抗体の活性を増強する抗体重鎖定常領域配列

Country Status (5)

Country Link
US (1) US12145993B2 (enExample)
EP (1) EP3470424B1 (enExample)
JP (3) JP2019528082A (enExample)
CN (2) CN107474136B (enExample)
WO (1) WO2017211321A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240110000A (ko) 2015-06-30 2024-07-12 샌포드 번햄 프레비즈 메디컬 디스커버리 인스티튜트 Btla 융합 단백질 작용제 및 이의 용도
WO2017211321A1 (zh) * 2016-06-08 2017-12-14 上海交通大学医学院 增强激动型抗体活性的抗体重链恒定区序列
CA3085472A1 (en) * 2017-12-19 2019-06-27 The Rockefeller University Human igg fc domain variants with improved effector function
CN109970856B (zh) 2017-12-27 2022-08-23 信达生物制药(苏州)有限公司 抗lag-3抗体及其用途
KR102813744B1 (ko) * 2017-12-27 2025-05-28 브리스톨-마이어스 스큅 컴퍼니 항-cd40 항체 및 그의 용도
CN110144009B (zh) * 2018-02-14 2020-01-21 上海洛启生物医药技术有限公司 Cd47单域抗体及其用途
KR20210096167A (ko) * 2018-11-28 2021-08-04 브리스톨-마이어스 스큅 컴퍼니 변형된 중쇄 불변 영역을 포함하는 항체
TWI756621B (zh) * 2019-01-25 2022-03-01 大陸商信達生物製藥（蘇州）有限公司 新型雙特異性抗體分子以及同時結合pd-l1和lag-3的雙特異性抗體
CA3136491A1 (en) * 2019-04-10 2020-10-15 Nankai University Anti-cd40 antibodies and uses thereof
CN110981958B (zh) * 2019-08-23 2020-10-20 四川大学华西医院 一种pd-l1抗体
CN112592404B (zh) * 2019-09-20 2023-07-25 上海交通大学医学院 抗体活性改造及其筛选方法
CN110862455B (zh) * 2019-12-03 2021-12-21 源道隆（苏州）医学科技有限公司 可结合cd47的多肽及其应用
AU2020398327A1 (en) 2019-12-03 2022-07-14 Evotec International Gmbh Interferon-associated antigen binding proteins and uses thereof
BR112022010757A2 (pt) * 2019-12-03 2022-08-16 Shanghai Jiao Tong Univ School Of Medicine Região de anticorpo fc com afinidade de ligação aumentada para fc-gama-riib.
LT4157876T (lt) 2020-05-26 2024-10-25 Boehringer Ingelheim International Gmbh Anti-pd-1 antikūnai
CN114591428B (zh) * 2020-12-04 2024-05-28 上海交通大学医学院 抗Dsg1抗体及其应用
KR102671409B1 (ko) * 2021-03-02 2024-05-31 진화섭 Cd30을 발현하는 세포에 독성을 나타내는 재조합 단백질 및 이를 유효성분으로 포함하는 암의 치료용 약학적 조성물
KR20250108092A (ko) * 2024-01-02 2025-07-15 젬파마테크 컴퍼니 리미티드 인간화 항체를 생성하는 동물 모델 및 그 제작 방법

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US7388079B2 (en) * 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
BRPI0510674A (pt) 2004-07-15 2007-12-26 Xencor Inc variantes fc otimizadas
MX2007001559A (es) * 2004-08-03 2007-04-10 Transtech Pharma Inc Proteinas de fusion de receptor para productos finales glicados avanzados y metodos de uso.
WO2007046834A2 (en) * 2004-12-22 2007-04-26 Centocor, Inc. Glp-1 agonists, compositions, methods and uses
WO2007067828A2 (en) * 2005-10-24 2007-06-14 Centocor, Inc. Glp-2 mimetibodies, polypeptides, compositions, methods and uses
JP5694921B2 (ja) * 2009-04-20 2015-04-01 協和発酵キリン株式会社 アミノ酸変異が導入されたＩｇＧ２を有する抗体
CA2822366A1 (en) 2010-12-23 2012-06-28 Janssen Biotech, Inc. Active protease-resistant antibody fc mutants
EP3604330A1 (en) * 2011-02-25 2020-02-05 Chugai Seiyaku Kabushiki Kaisha Fcgammariib-specific fc antibody
EP2537864B1 (en) * 2011-06-24 2019-08-07 Laboratoire Français du Fractionnement et des Biotechnologies Fc variants with reduced effector functions
EP2762493B1 (en) * 2011-09-30 2021-06-09 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
KR102475951B1 (ko) * 2012-02-24 2022-12-08 추가이 세이야쿠 가부시키가이샤 ＦｃγＲＩＩＢ를 매개로 항원의 소실을 촉진하는 항원 결합 분자
KR20150013503A (ko) * 2012-05-11 2015-02-05 머크 샤프 앤드 돔 코포레이션 표면 앵커링된 경쇄 미끼 항체 디스플레이 시스템
TWI855488B (zh) * 2012-08-24 2024-09-11 日商中外製藥股份有限公司 FcγRIIb特異性Fc區域變異體
EP2914627B1 (en) 2012-10-30 2021-04-07 Apexigen, Inc. Anti-cd40 antibodies and methods of use
TWI635098B (zh) * 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
KR20160006168A (ko) * 2013-03-18 2016-01-18 바이오서오엑스 프로덕스 비.브이. 인간화 항-cd134(ox40) 항체 및 이의 용도
JP6633520B2 (ja) * 2013-11-12 2020-01-22 オージーディー２ ファーマ プロアポトーシス活性を有するヒトｉｇｇ１由来抗体
JOP20200096A1 (ar) * 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
AU2015248785A1 (en) * 2014-04-16 2016-11-24 Ucb Biopharma Sprl Multimeric Fc proteins
SMT202100116T1 (it) 2014-05-28 2021-05-07 Agenus Inc Anticorpi anti-gitr e metodi di utilizzo degli stessi
US20170196971A1 (en) * 2014-06-05 2017-07-13 The Board Of Trustees Of The University Of Arkansas Antibody guided vaccines and methods of use for generation of rapid mature immune responses
DK3221363T3 (da) * 2014-11-21 2020-08-10 Bristol Myers Squibb Co Antistoffer mod cd73 og anvendelser deraf
HRP20201756T8 (hr) * 2014-11-21 2021-08-20 Bristol-Myers Squibb Company Antitijela koja sadrže modificirane regije teškog lanca
BR112018010172A2 (pt) * 2015-11-19 2018-11-21 Bristol Myers Squibb Co anticorpos contra receptor de fator de necrose de tumor induzido por glicocorticoide (gitr) e usos dos mesmos
WO2017211321A1 (zh) * 2016-06-08 2017-12-14 上海交通大学医学院 增强激动型抗体活性的抗体重链恒定区序列
CN108623686A (zh) 2017-03-25 2018-10-09 信达生物制药(苏州)有限公司 抗ox40抗体及其用途
BR112022010757A2 (pt) * 2019-12-03 2022-08-16 Shanghai Jiao Tong Univ School Of Medicine Região de anticorpo fc com afinidade de ligação aumentada para fc-gama-riib.
CN115461122A (zh) * 2020-05-01 2022-12-09 博尔特生物治疗药物有限公司 抗dectin-2抗体
CN114106174A (zh) * 2020-08-27 2022-03-01 苏州景涞医疗科技有限公司 低毒性抗ox40抗体、其药物组合物及应用

Similar Documents

Publication Publication Date Title
JP2019528082A5 (enExample)
US12384850B2 (en) Guidance and navigation control proteins and method of making and using thereof
US12029761B2 (en) Guidance and Navigation Control proteins and method of making and using thereof
CN107474136B (zh) 增强激动型抗体活性的抗体重链恒定区序列
JP2020530289A5 (enExample)
JP2020521452A (ja) 標的化免疫寛容
CA3174097A1 (en) T-cell modulatory polypeptides with conjugation sites and methods of use thereof
JP2017524367A5 (enExample)
JP2018512430A5 (enExample)
JP2018503399A5 (enExample)
CN107847587A (zh) Cd30×cd16抗体与pd‑1拮抗剂的联合药物用于治疗
JP2023541771A (ja) リガンド－受容体対及び生物学的に機能的なタンパク質を含む融合タンパク質
JP2017533207A5 (enExample)
CA3058262A1 (en) Chimeric polypeptides and methods of altering the membrane localization of the same
JPWO2020069133A5 (enExample)
CN114853903A (zh) Btla融合蛋白激动剂及其用途
CN115515981A (zh) 抗肿瘤相关抗原抗体及其用途
JP2023515196A (ja) 脂肪酸分子とコンジュゲートされた抗体及びその使用
WO2023147331A1 (en) Bispecific molecule with tunable affinity to a targetted antigen
WO2023177974A2 (en) Anti-mesothelin antibodies and uses thereof
AU2023218343A1 (en) Anti-il13ra2 antibodies and uses thereof
KR20250102074A (ko) 항-5t4 항체 및 이의 용도
CN120187757A (zh) 抗EGFRvIII抗体及其用途
WO2024182475A2 (en) Anti-ror2 antibodies and uses thereof
WO2024076864A2 (en) Anti-ror1 antibodies and uses thereof